Every 8-K that AngioDynamics, Inc. (ANGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANGO filings page.
AngioDynamics reported fiscal 2027 first-quarter net sales of $80.9 million, up 6.9% year over year. Med Tech sales increased 13.2% to $39.9 million, while Med Device sales rose 1.4% to $41.0 million. Gross margin was 59.4%, 410 basis points higher than a year earlier; GAAP net loss was $7.1 million versus $10.9 million, and adjusted EBITDA was $5.0 million versus $2.2 million. Operating cash use was $15.3 million; cash was $34.0 million with no debt at August 31, 2026.
The company reiterated fiscal 2027 guidance and expects gross margin to be lower in the second half than in the first half. Eric Honroth was appointed President and Chief Executive Officer effective November 2, 2026, succeeding Jim Clemmer, who will remain as an executive advisor. The FDA approved the IDE for the RELIEF feasibility study of NanoKnife for benign prostatic hyperplasia; the study is designed for 40 subjects at up to five U.S. sites, with a six-month symptom-score endpoint.
AngioDynamics appointed Eric Honroth as president and chief executive officer effective November 2, 2026, succeeding James C. Clemmer, who will retire from those roles and leave the board. Honroth is also to join the board on that date, contingent on beginning CEO service and Clemmer's board retirement. Honroth most recently served as President Life Science at Getinge AB from 2018 to 2026.
Honroth's agreement sets a $735,000 annual base salary and a target annual bonus of 95% of salary. Contingent on starting the role, he will receive a $1,487,116 long-term incentive award split equally between restricted stock units and performance share units, a $450,000 replacement restricted-stock-unit award vesting on the first and second anniversaries, and a $350,000 cash sign-on bonus. The agreement also provides a $10,000 monthly commuting and temporary living allowance for up to 24 months and a $24,000 annual automobile allowance. Clemmer will consult through the first anniversary of the effective date, unless earlier terminated, for $30,000 monthly. Retention agreements provide for equity acceleration for covered executives under stated employment conditions.
AngioDynamics reported record fiscal 2026 results, with pro forma net sales of $320.2 million, up 9.4% from a year earlier, and fourth‑quarter net sales of $86.6 million, up 8.0%. Med Tech revenue grew 18.4% to $150.0 million, while Med Device revenue rose 2.5% to $170.2 million, lifting gross margin to 54.6%.
Despite stronger sales, the company posted a GAAP net loss of $36.7 million, or $0.88 per share, though adjusted net loss was $10.0 million and adjusted EBITDA increased to $13.2 million from $7.6 million. Cash from operations was $3.1 million for the year, and AngioDynamics ended May 31, 2026 with $53.9 million in cash and a debt‑free balance sheet.
Growth was led by the Auryon atherectomy system, Mechanical Thrombectomy portfolio and NanoKnife platform, which benefited from new clinical data, FDA IDE approvals and improved reimbursement including Category I CPT codes and a Medicare local coverage determination. For fiscal 2027, the company guides net sales to $336–$341, Med Tech growth of 12–15%, gross margin of 54–55%, and adjusted EBITDA of $13–$16.
AngioDynamics reported fiscal Q3 2026 results showing solid Med Tech–led growth but continued GAAP losses. Net sales were $78.4 million, up 8.9% year over year, with Med Tech revenue of $37.3 million growing 19.0% and Med Device revenue of $41.1 million up 1.1%.
Gross margin was 52.9%, down 110 basis points, reflecting tariffs, inflation and manufacturing transition costs. The company posted a GAAP net loss of $8.1 million, or ($0.19) per share, and a pro forma adjusted net loss of $3.0 million, or ($0.07) per share, while pro forma adjusted EBITDA improved to $1.8 million.
AngioDynamics ended the quarter with $37.8 million in cash and no debt. It raised full-year 2026 guidance, now expecting net sales of $313.5–$315.5 million, Med Tech growth of 15–17%, adjusted EBITDA of $10.0–$12.0 million, and adjusted EPS between ($0.30) and ($0.23).
AngioDynamics outlined a planned leadership transition and retention program for senior executives. President and CEO James C. Clemmer signed a Transition and Retirement Agreement under which he will continue as CEO until a successor is appointed or until November 30, 2026, with possible month‑to‑month extensions by mutual agreement. His existing stock options and service-based restricted stock units will continue to vest until his service as a consultant or director ends, after which they immediately vest, while performance-based restricted stock units may still vest according to their original terms. The board also approved retention agreements for the executive leadership team: key named executive officers are eligible for cash retention awards equal to 150% of base salary and others for 50% of base salary, if they remain employed until the earlier of six months after the new CEO starts or June 1, 2027.
AngioDynamics, Inc. filed a current report after its President and CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. The company has made the conference presentation slides available as Exhibit 99.1, furnishing them for informational purposes.
The report clarifies that these slides are furnished rather than filed, meaning they are not subject to certain liability provisions and are not automatically incorporated into other securities filings. It also includes a detailed caution about forward-looking statements, noting that expectations about strategy, products, financial position and growth are subject to numerous risks, including regulatory actions, economic conditions, competition, supply chain challenges and factors described in prior AngioDynamics SEC reports.
AngioDynamics, Inc. reported stockholder voting results. Shareholders elected two directors: James C. Clemmer received 29,634,152 votes for and 800,454 withheld, with 5,462,943 broker non-votes; Michael E. Tarnoff, MD received 29,245,896 votes for and 1,188,710 withheld, with 5,462,943 broker non-votes.
Stockholders also approved two additional items. One item received 35,727,186 votes for, 156,899 against, and 13,464 abstentions; there were no broker non-votes for this item. Another item received 28,357,782 votes for, 2,057,982 against, 18,842 abstentions, and 5,462,943 broker non-votes.
AngioDynamics, Inc. filed a current report to furnish its financial results for the fiscal first quarter ended August 31, 2025. The company issued a press release with these results, attached as Exhibit 99.1, and also provided investor presentation slides discussing the quarter as Exhibit 99.2.
The company emphasizes that these materials are being furnished rather than filed, which limits certain securities law liabilities and controls how they are incorporated into other SEC documents. It also includes extensive forward-looking statement language, highlighting risks such as the impact of COVID-19, regulatory actions, competition, product development, litigation, economic conditions, and other factors referenced in its latest annual report.
AngioDynamics, Inc. (NASDAQ: ANGO) filed a Form 8-K on July 15, 2025 to furnish—rather than file—materials related to its fiscal fourth-quarter and full-year results ended May 31, 2025.
- Item 2.02: The company issued a press release (Exhibit 99.1) announcing its Q4 and FY 2025 financial performance.
- Item 7.01: Investor presentation slides (Exhibit 99.2) discussing the same period were also provided.
- Both exhibits are expressly excluded from Exchange Act Section 18 liability and will not be incorporated into future Securities Act or Exchange Act filings unless specifically referenced.
- No quantitative results, guidance, or commentary appear in the 8-K text itself; investors must review the furnished exhibits for details.
The filing contains standard forward-looking-statement disclaimers and lists common risk factors that could cause actual results to differ.